- Home
- REVB vs PRFX Comparison
REVB vs PRFX Comparison
Compare REVB & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- PRFX
- Stock Information
- Founded
- REVB 2020
- PRFX 2007
- Country
- REVB United States
- PRFX Israel
- Employees
- REVB N/A
- PRFX N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- PRFX Health Care
- Exchange
- REVB Nasdaq
- PRFX Nasdaq
- Market Cap
- REVB 3.4M
- PRFX 2.8M
- IPO Year
- REVB N/A
- PRFX 2020
- Fundamental
- Price
- REVB $1.35
- PRFX $1.30
- Analyst Decision
- REVB
- PRFX Hold
- Analyst Count
- REVB 0
- PRFX 1
- Target Price
- REVB N/A
- PRFX N/A
- AVG Volume (30 Days)
- REVB 195.9K
- PRFX 160.7K
- Earning Date
- REVB 11-07-2025
- PRFX 11-14-2025
- Dividend Yield
- REVB N/A
- PRFX N/A
- EPS Growth
- REVB N/A
- PRFX N/A
- EPS
- REVB N/A
- PRFX N/A
- Revenue
- REVB N/A
- PRFX N/A
- Revenue This Year
- REVB N/A
- PRFX N/A
- Revenue Next Year
- REVB N/A
- PRFX N/A
- P/E Ratio
- REVB N/A
- PRFX N/A
- Revenue Growth
- REVB N/A
- PRFX N/A
- 52 Week Low
- REVB $1.15
- PRFX $1.20
- 52 Week High
- REVB $60.48
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- REVB 42.07
- PRFX 46.80
- Support Level
- REVB $1.23
- PRFX $1.25
- Resistance Level
- REVB $1.38
- PRFX $1.34
- Average True Range (ATR)
- REVB 0.08
- PRFX 0.08
- MACD
- REVB 0.03
- PRFX 0.01
- Stochastic Oscillator
- REVB 57.65
- PRFX 40.82
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.